Heidi Unveils Heidi II With Agents for Administrative Work

Heidi unveiled Heidi II on September 28, 2026, a new version of its clinical AI platform that the Melbourne, Australia-based company said takes action on the administrative work surrounding each patient visit rather than only documenting the visit. The company said the platform currently supports 2.8 million patient visits every week globally.

Agents, Memory and Peer-Reviewed Research

According to the company, those visits surface around 10 million follow-up tasks that until now were handed back to the clinician. Heidi II introduces three capabilities the company names Agents, Memory, and Peer-reviewed research, and it said those tasks can now be acted on inside clinical workflows under clinician supervision.

The announcement describes administrative work as consuming an increasing share of clinical time across health systems globally, and cited research estimating that the average doctor spends 8.7 hours a week, or 16.6% of working hours, on administration.

Thomas Kelly, Co-Founder and CEO of Heidi, called the release “the culmination of our work at Heidi.” “We started inside the visit by capturing the note and gathering the care context,” he said. “Now Heidi can create the tasks and complete them from referrals and chart prep to arranging follow ups. It handles that work as a partner, while clinical judgement and approvals remain with the clinician.”

How the Agents Work

A new Home screen opens on the clinician’s day and consolidates patients, sessions and tasks with the relevant context already loaded, according to the announcement. Sessions, patients and sources can be attached as references, and external files can be uploaded for additional context. From there, a clinician can ask Heidi to complete a task in plain language, and Heidi starts an agent that plans and executes the work, then returns the result for review without needing to be re-prompted at every step.

Early use cases listed in the announcement include pre-charting a full day’s patients, performing evidence-based analyses on a practice’s visits or referral communications, and running panel sweeps to identify patients due for immunizations, blood tests, screening or recalls.

Raymond Brown, MD, of Capital ENT & Sinus Center, said in the announcement: “Heidi does the preparation I used to squeeze in between patients. It loads my schedule, finds the pathology results in the chart, and writes a pre-visit note I can read in thirty seconds.”

Agents can be saved and scheduled as Routines, either for an individual clinician or an entire practice, and run across a patient list rather than one patient at a time. The company said Heidi II can also use the computer across the systems a practice runs on, including the record, the calendar, the inbox and the portal, and that when Heidi cannot complete a task, it says so and explains why.

The company said every agentic run in Heidi II is designed around the principle that agents in healthcare need supervision and should be met with friction. Clinical judgment remains with the clinician, with approval controls applied according to the workflow and settings configured by the clinician or organization. Capabilities are staged by region and setting, and the company said dedicated internal clinical safety teams review features through a clinical risk lens before and after release.

Platform Scale and Recent Funding

Heidi said its Scribe has supported more than 175 million visits and 67 million clinical hours globally, that Heidi Evidence has answered more than 10 million queries since launch, and that the platform has surfaced more than 400 million follow-on tasks since February 2024. The company describes its ambition as doubling the world’s capacity for care.

On September 23, 2026, the company announced it had secured US$340 million in new funding: a $100 million Series C round led by Blackbird, with participation from existing investors including Phoenix Court, Point72 Private Investments and Headline, alongside a $240 million growth investment led by General Catalyst’s Customer Value Fund. Heidi said the new investment values the company at $900 million.

In that announcement, the company said it had scaled annual recurring revenue from $1 million to $50 million in two years, and it named NHS Midlands, Metro South Health, Health New Zealand and Beth Israel Lahey Health among the public systems and networks using its platform.

Evidence Content, Connectors and Availability

The company said peer-reviewed research from content partners including the New England Journal of Medicine, Wiley and Cochrane, alongside BMJ Group’s clinical decision support information, will be brought into every chat, with citations that journal subscribers can follow to the full article.

New connectors allow Heidi to work with existing practice systems, from pulling appointment lists and answering questions from the electronic health record to reading and writing appointments and clinical mail, or following a practice’s documented process from a standard operating procedure.

Heidi said Heidi II begins rolling out on September 29, 2026 in English and French, with additional languages to follow. The company said these product capabilities will not be available in the UK or EU.